#### J Nephropharmacol. 2015; 4(1): 23-25.



http://www.jnephropharmacology.com

# Journal of Nephropharmacology



# **Prevention of contrast induced nephropathy; a cardiology point of view**

# Mohammad Hashemi<sup>1</sup>, Mohaddeseh Behjati<sup>2,3\*</sup>, Shiva Izadi<sup>3</sup>

<sup>1</sup>Departmentof Cardiology, Isfahan University of Medical Sciences, Isfahan, Iran <sup>2</sup>Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran <sup>3</sup>Isfahan Heart Failure Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

#### ARTICLEINFO

*Article Type:* Hypothesis

Article History:

Received: 14 October 2014 Accepted: 18 December 2014 ePublished: 1 January 2015

#### Keywords:

Contrast induced nephropathy Renal failure Contrast media

# Implication for health policy/practice/research/medical education:

Contrast induced nephropathy (CIN) is one of the most common causes of hospital-acquired renal insufficiency. Among risk factors for susceptibility to CIN, the most commonly reported risk factors includes diabetes mellitus, hypotension, hypertension, pre-existing renal failure, anti-hypertensive agents, high total contrast volume and osmolality, advanced age and female gender.

*Please cite this paper as:* Hashemi M, Behjati M, Izadi S. Prevention of contrast induced nephropathy; a cardiology point of view. J Nephropharmacol 2015; 4(1): 23-25.

y increasing the number of cardiovascular procedures, iodinated contrast media (ICM) is one of the most common agents used for diagnostic and prognostic and also therapeutic cardiac interventions. Contrast induced nephropathy (CIN) is one of the most leading causes of hospital-acquired renal insufficiency (1). Following cardiovascular invasive procedures, CIN occurs in about 3.1 to 31% of patients (2). CIN induces unfavorable outcomes and is associated with increased morbidity and mortality rate in hospitalized patients (3). This is a multifactorial disease, however, various pathophysiologic mechanisms have been attributed to development of CIN such as; direct toxicity to tubular cells, renal ischemia and hypoperfusion, oxidative stress, direct pro-apoptotic effects, altered vasomotor balance, enhanced vasoconstriction due to increased adenosine, endothelin, free radicals and decreased vasodilation due to diminished nitric oxide and prostaglandin levels (Figure 1) (4). Consequently, decreased renal perfusion and medullary ischemia contribute to the development and progression of CIN, but the real cause is still unknown (5,6). Hereby, we are going to introduce a memorial name for better identification of at risk patients derived from the risk factors with strongest odd's ratio.

In a survey of full-text searches of electronic databases we have collected risk factors for CIN. Among them, the most common reported risk factors were focused. This would not be a scoring system but this acronym introduce an easy memorial name in order to estimate risk factors of CIN in cases undergoing coronary angiography and intervention to prevent occurrence of CIN.

Since the most commonly reported risk factors related to the occurrence of CIN were hypotension/hypertension/ heart failure/hemodynamic instability, diabetes mellitus (DM), renal insufficiency, agents as antihypertensive drugs, antibiotics, non-steroidal anti-inflammatory drugs/ anemia, total contrast volume and type, elderly, female gender; the memorial word could be hydrate-her (7-11). Hereby, we introduce a memorial prediction system based on the predisposing risk factors with strongest odds ratio for development of CIN. Regarding hydrateher, a brief explanation is provided in the following section. Hemodynamic instability extremely predisposes patients to the development of CIN as in the case of intraaortic balloon use and sepsis (7,12). Pre-existing renal insufficiency has been defined as creatinine level of >1.2 mg/dl (13). Indeed, patients with glomerular filtration rate (GFR) level below 30 ml/min, 30-60 ml/min and >60 ml/

\*Corresponding author: Mohaddeseh Behjati, Heart Failure Research Center, Isfahan Heart Failure Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. Email: behjati@med.mui.ac.ir

#### Hashemi M et al



Figure 1. Pathophysiology of contrast induced nephropathy (CIN)

min were considered as high risk patients, moderate risk and low risk, respectively (14). Hypotension was defined by some experts as systolic blood pressure <80 mmHg for at least 1 hour which requires inotropic support. High total contrast volume was suggested as total dose of contrast >200 ml (15). Indeed, the role of osmolality of contrast media has been well elucidated previously. Higher rate of CIN was seen using high osmolality contrast media (>1500 mOsm/kg) compared with low-osmolality (550-850 mOsm/kg) (16). Among anti-hypertensive agents, angiotensin converting enzyme inhibitors (ACEI) and renin-angiotensin blockers (RAS blockers) were most paid attention agents. Age more than 75 years old is considered as a potent risk factor for susceptibility to CIN occurrence (10). Avoidance of unnecessary hypoxia and hypotension, using minimum amount of contrast agent and withdrawal of nephrotoxic drugs seem to be the best preventive measures. Some therapeutic options as forced dieresis by adequate volume expansion, bicarbonate sodium, n-acetylcysteine and statins are advised (17,18). But since, current therapeutic strategies are not so effective for CIN, routine prediction and identification of at-risk cases, prevention of its occurrence and early detection are so beneficial. In the cases with any of above mentioned risk factors, hydration is the best practical approach for prevention of CIN. Indeed, the total contrast volume should be reduced to diminish the rate of CIN. Thus, physicians could predict cases at risk for development of CIN that could predict the occurrence of CIN by this memorial phrase.

Using this approach, cases with 0 score are at the lowest risk state. In cases that have a risk factor embedded in this memorial name should be hydrated well before the procedure.

# Conclusion

CIN is one of the most common causes of hospital-acquired renal insufficiency. Among risk factors for susceptibility to CIN, the most commonly reported risk factors includes diabetes mellitus, hypotension, hypertension, pre-existing renal failure, antihypertensive agents, high total contrast volume and osmolality, advanced age and female gender.

# Authors' contributions

All authors contributed to the manuscript equally.

#### **Conflict of interests**

The authors declared no competing interests.

# **Ethical considerations**

Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission, redundancy) have been completely observed by the authors.

# **Funding/Support**

None.

# References

- Jorgensen AL. Contrast-inducednephropathy: pathophysiology and preventive strategies. Crit Care Nurse 2013; 33(1): 37-46.
- Caixeta A, Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. Catheter Cardiovasc Interv 2010; 75 Suppl 1: S15-20.
- McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103(5): 368-75.
- Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68: 14-22.
- Seifirad S, Masoudkabir F. Apelin could reduce risk of contrast-induced nephropathy in patients with congestive heart failure. Med Hypotheses 2013; 81(5): 898-900.
- Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging 2013; 4(6): 811-20.
- Koo HM, Doh FM, Ko KI, Kim CH, Lee MJ, Oh HJ, et al. Diastolic dysfunction is associated with an increased risk of contrast-inducednephropathy: a retrospective cohort study. BMC Nephrol 2013; 14: 146.
- Golshahi J, Nasri H, Gharipour M. Contrast-induced nephropathy; A literature review. J Nephropathol 2014; 3(2): 51-6.
- 9. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113(14): 1799-806.
- Rosenstock JL, Gilles E, Geller AB, Panagopoulos G, Mathew S, Malieckal D, et al. Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. Int Urol Nephrol 2010; 42(4): 1049-54.

- 11. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003; 15(1): 18-22.
- Clec'h C, Razafimandimby D, Laouisset M, Chemouni F, Cohen Y. Incidence and outcome of contrastassociated acute kidney injury in a mixed medicalsurgical ICU population: a retrospective study. BMC Nephrol 2013; 14: 31.
- Cheruvu B, Henning K, Mulligan J, Klippenstein D, Lawrence D, Gurtoo L, et al. Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations. J Comput Assist Tomogr 2007; 31(4): 493-8.
- 14. Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialtyspecific protocols for interventional radiology,

diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc 2009; 84(2): 170-9.

- Fu N, Li X, Yang S, Chen Y, Li Q, Jin D, et al. Risk score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention. Angiology 2013; 64(3): 188-94.
- 16. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005; 68(5): 2256-63.
- Zaraca F, Wiedermann CJ, Ebner H. Contrast media-induced nephropathy in patients undergoing angiography prior to or during vascular surgery: a systematic review. Minerva Chir 2011;66(6):553-60.
- Brophy D. Role of n-acetylcysteine in the prevention of radiocontrast induced nephropathy. Ann Pharmacother 2002; 36: 1466-70.

**Copyright** © 2015 The Author(s); Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.